TY - JOUR
T1 - Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease
AU - for the LRRK2 Ashkenazi Jewish Consortium58
AU - Alcalay, Roy N.
AU - Mejia-Santana, Helen
AU - Mirelman, Anat
AU - Saunders-Pullman, Rachel
AU - Raymond, Deborah
AU - Palmese, Christina
AU - Caccappolo, Elise
AU - Ozelius, Laurie
AU - Orr-Urtreger, Avi
AU - Clark, Lorraine
AU - Giladi, Nir
AU - Bressman, Susan
AU - Marder, Karen
AU - Tang, Ming X.
AU - Santana, Helen Mejia
AU - Roos, Ernest
AU - Orbe-Reilly, Martha
AU - Fahn, Stanley
AU - Cote, Lucien
AU - Waters, Cheryl
AU - Mazzoni, Pietro
AU - Ford, Blair
AU - Louis, Elan
AU - Levy, Oren
AU - Rosado, Llency
AU - Ruiz, Diana
AU - Dorovski, Tsvyatko
AU - Greene, Paul
AU - Marder, Karen S.
AU - Gurevich, Tanya
AU - Shira, Anat Bar
AU - GanaWeisz, Mali
AU - Yasinovsky, Kira
AU - Zalis, Maayan
AU - Thaler, Avner
AU - Balash, Yaacov
AU - Hertzel, Shabtai
AU - Gan, Ziv
AU - Kobo, Hila
AU - Hillel, Ariella
AU - Shkedy, Anat
AU - Deik, Andres
AU - Barrett, Matthew James
AU - Cabassa, Jose
AU - Groves, Mark
AU - Hunt, Ann L.
AU - Lubarr, Naomi
AU - Luciano, Marta San
AU - Miravite, Joan
AU - Sachdev, Rivka
N1 - Publisher Copyright:
© 2014 Elsevier Ltd.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Background: Ashkenazi Jewish (AJ) LRRK2 carriers are more likely to manifest the postural instability gait difficulty (PIGD) motor phenotype than non-carriers but perform similarly to non-carriers on cognitive screening tests. Objective: To compare the cognitive profiles of AJ with Parkinson's disease (PD) with and without LRRK2 G2019S mutations using a comprehensive neuropsychological battery. Methods: We administered a neuropsychological battery to PD participants in the Michael J. Fox Foundation AJ consortium. Participants (n=236) from Beth Israel Medical Center, NY, Columbia University Medical Center, NY and Tel Aviv Medical Center, Israel included 116 LRRK2 G2019S carriers and 120 non-carriers. Glucocerbrosidase mutation carriers were excluded. We compared performance on each neuropsychological test between carriers and non-carriers. Participants in New York (n=112) were evaluated with the entire battery. Tel Aviv participants (n=124) were evaluated on attention, executive function and psychomotor speed tasks. The association between G2019S mutation status (predictor) and each neuropsychological test (outcome) was assessed using linear regression models adjusted for PIGD motor phenotype, site, sex, age, disease duration, education, Unified Parkinson's Disease Rating Scale (UPDRS) Part III, levodopa equivalent dose, and Geriatric Depression Score (GDS). Results: Carriers had longer disease duration (p<0.001) and were more likely to manifest the PIGD phenotype (p=0.024). In adjusted regression models, carriers performed better than non-carriers in Stroop Word Reading (p<0.001), Stroop Interference (p=0.011) and Category Fluency (p=0.026). Conclusion: In AJ-PD, G2019S mutation status is associated with better attention (Stroop Word Reading), executive function (Stroop Interference) and language (Category Fluency) after adjustment for PIGD motor phenotype.
AB - Background: Ashkenazi Jewish (AJ) LRRK2 carriers are more likely to manifest the postural instability gait difficulty (PIGD) motor phenotype than non-carriers but perform similarly to non-carriers on cognitive screening tests. Objective: To compare the cognitive profiles of AJ with Parkinson's disease (PD) with and without LRRK2 G2019S mutations using a comprehensive neuropsychological battery. Methods: We administered a neuropsychological battery to PD participants in the Michael J. Fox Foundation AJ consortium. Participants (n=236) from Beth Israel Medical Center, NY, Columbia University Medical Center, NY and Tel Aviv Medical Center, Israel included 116 LRRK2 G2019S carriers and 120 non-carriers. Glucocerbrosidase mutation carriers were excluded. We compared performance on each neuropsychological test between carriers and non-carriers. Participants in New York (n=112) were evaluated with the entire battery. Tel Aviv participants (n=124) were evaluated on attention, executive function and psychomotor speed tasks. The association between G2019S mutation status (predictor) and each neuropsychological test (outcome) was assessed using linear regression models adjusted for PIGD motor phenotype, site, sex, age, disease duration, education, Unified Parkinson's Disease Rating Scale (UPDRS) Part III, levodopa equivalent dose, and Geriatric Depression Score (GDS). Results: Carriers had longer disease duration (p<0.001) and were more likely to manifest the PIGD phenotype (p=0.024). In adjusted regression models, carriers performed better than non-carriers in Stroop Word Reading (p<0.001), Stroop Interference (p=0.011) and Category Fluency (p=0.026). Conclusion: In AJ-PD, G2019S mutation status is associated with better attention (Stroop Word Reading), executive function (Stroop Interference) and language (Category Fluency) after adjustment for PIGD motor phenotype.
KW - Genetics
KW - LRRK2
KW - Neuropsychological tests
KW - Parkinson
UR - http://www.scopus.com/inward/record.url?scp=84921357548&partnerID=8YFLogxK
U2 - 10.1016/j.parkreldis.2014.09.033
DO - 10.1016/j.parkreldis.2014.09.033
M3 - Article
AN - SCOPUS:84921357548
SN - 1353-8020
VL - 21
SP - 106
EP - 110
JO - Parkinsonism and Related Disorders
JF - Parkinsonism and Related Disorders
IS - 2
ER -